Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Value of Medical Innovation in Mantle Cell Lymphoma The incidence of cancer continues to increase worldwide. In recent years, substantial progress has been made through medical innovation to help people manage diseases such as cancer, allowing them to live longer.1 Much work remains to be done, however, particularly for rare diseases that have not historically been a focus of medical innovations. MCL Mantle cell lymphoma (MCL) is a sub-type of lymphoma—a cancer of white blood cells called lymphocytes, which normally help the body fight infection. Lymphomas, which usually begin in the lymph nodes, are divided in two categories: Hodgkin lymphoma and non-Hodgkin lymphoma (NHL), which is further divided into several sub-types, including MCL.2 NHL lymphoma Incidence of NHL has increased:1 90 % 1975 MCL 10% % 49.9% as of 1990 1990 1992 1994 1998 2000 Despite advances in the treatment of NHL as a whole, the survival rate for patients with MCL remains considerably lower. as of 2005 54.6% as of 2009 2004 2006 2008 2005 Pre-1995 Chemotherapy is the standard treatment for NHL 1995 Autologous bone marrow transplantation improves survival for patients with diffuse large B-cell lymphoma4 ½ 2002 of NHLs3 70.6% 41 MCL year year 1 rate survival rate 1 survival less than accounts for 2010 5 5 NHL Hodgkin 1997 Proteasome inhibitor approved by FDA4 2002 Radioimmunotherapy approved by FDA4 2010 2008 Antifolate approved by the FDA4 First targeted therapy approved by FDA4 Roughly of people diagnosed with MCL are over the age of 68 about 4,000 new cases of MCL are diagnosed in the United States each year2 Men are more than 60% more likely to be affected by NHL than woman2 Caucasians are over 55% 509,065 people living with NHL5 69,740 expected new cases of NHL in 20135 more likely to be affected by NHL than African Americans2 1. National Cancer Institute. Surveillance Epidemiology and End Results (SEER). April 2012. Available at http://seer.cancer.gov. Accessed May 2013. 2. Leukemia and Lymphoma Society. Mantle Cell Lymphoma Facts. July 2012. 3. Li ZM, Zucca E, Ghielmini M. Open questions in the management of mantle cell lymphoma. Cancer Treat Rev. 2013. doi: 10.1016/j.ctrv.2012.12.013. 4. American Society of Clinical Oncology. Progress Against Lymphoma. May 2013. 5. National Cancer Institute. SEER Stat Fact Sheets: Non-Hodgkin Lymphoma. May 2013. Available at http://seer.cancer.gov/statfacts/html/nhl.html. 6. Shah BD, Martin P, Sotomayor EM. Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches. Cancer Control. 2012;19:227-235.